Marie-Anne van Stam1, Neil K Aaronson2, J L H Ruud Bosch3, Jacobien M Kieffer2, Jochem R N van der Voort van Zyp4, Corinne N Tillier5, Simon Horenblas6, Henk G van der Poel7. 1. Department of Urology, Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands; Division of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 2. Division of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 3. Department of Urology, Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. 5. Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 6. Department of Urology, Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 7. Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: h.vd.poel@nki.nl.
Abstract
BACKGROUND: Well-documented reports of patients' experiences with different treatments are important for helping localised prostate cancer (LPC) patients choose among the available treatment options. OBJECTIVE: To document differences in patient-reported outcomes (PROs) following radical prostatectomy (RP), external beam radiotherapy (EBRT), brachytherapy (BT), and active surveillance (AS), and to evaluate how these PROs and other factors are associated with treatment decision regret. DESIGN, SETTING, AND PARTICIPANTS: A prospective, observational, multicentre study of men diagnosed with LPC (stage cT1-2) during 2014-2016. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients completed validated PRO measures (Quality of Life Questionnaire Core 30 [QLQ-C30], Quality of Life Questionnaire prostate cancer-specific module [QLQ-PR25], Decision Regret Scale, and the Memorial Anxiety Scale for Prostate Cancer) before treatment and at 3, 6, and 12mo after treatment. Mixed-effect models were used to describe different PRO patterns. RESULTS AND LIMITATIONS: The analytic cohort included 434 men (AS=32%; RP=45%; EBRT=12%; BT=10%). Follow-up response rates were above 90%. At 1-yr follow-up, (1) men who had received RP reported significantly (p<0.01) more urinary incontinence, sexual dysfunction, hormonal/masculinity-related symptoms, and less emotional distress; (2) those having received EBRT reported more sexual dysfunction, hormonal/masculinity-related symptoms, and physical distress; and (3) those having received BT reported more urinary obstruction and irritation symptoms, compared with patients under AS. Irrespective of the treatment modality, 23% of the patients reported clinically relevant treatment regret (99% confidence interval, 17-28%). Multivariate correlates of decision regret were hormonal/masculinity-related symptoms, educational level, and positive surgical margins. CONCLUSIONS: Post-treatment physical and psychosocial functioning was significantly associated with specific treatment modalities and pretreatment functioning. Regret was relatively frequently reported by patients who experienced unwanted physical, psychosocial, and oncological outcomes. Greater efforts should be made to understand whether carefully educating patients about the possible consequences and effectiveness of treatments may help limit the feeling of treatment regret. PATIENT SUMMARY: In men with localised prostate cancer, regret about the treatment choice was more common among those who experienced more treatment-related symptoms during the year after treatment.
BACKGROUND: Well-documented reports of patients' experiences with different treatments are important for helping localised prostate cancer (LPC) patients choose among the available treatment options. OBJECTIVE: To document differences in patient-reported outcomes (PROs) following radical prostatectomy (RP), external beam radiotherapy (EBRT), brachytherapy (BT), and active surveillance (AS), and to evaluate how these PROs and other factors are associated with treatment decision regret. DESIGN, SETTING, AND PARTICIPANTS: A prospective, observational, multicentre study of men diagnosed with LPC (stage cT1-2) during 2014-2016. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients completed validated PRO measures (Quality of Life Questionnaire Core 30 [QLQ-C30], Quality of Life Questionnaire prostate cancer-specific module [QLQ-PR25], Decision Regret Scale, and the Memorial Anxiety Scale for Prostate Cancer) before treatment and at 3, 6, and 12mo after treatment. Mixed-effect models were used to describe different PRO patterns. RESULTS AND LIMITATIONS: The analytic cohort included 434 men (AS=32%; RP=45%; EBRT=12%; BT=10%). Follow-up response rates were above 90%. At 1-yr follow-up, (1) men who had received RP reported significantly (p<0.01) more urinary incontinence, sexual dysfunction, hormonal/masculinity-related symptoms, and less emotional distress; (2) those having received EBRT reported more sexual dysfunction, hormonal/masculinity-related symptoms, and physical distress; and (3) those having received BT reported more urinary obstruction and irritation symptoms, compared with patients under AS. Irrespective of the treatment modality, 23% of the patients reported clinically relevant treatment regret (99% confidence interval, 17-28%). Multivariate correlates of decision regret were hormonal/masculinity-related symptoms, educational level, and positive surgical margins. CONCLUSIONS: Post-treatment physical and psychosocial functioning was significantly associated with specific treatment modalities and pretreatment functioning. Regret was relatively frequently reported by patients who experienced unwanted physical, psychosocial, and oncological outcomes. Greater efforts should be made to understand whether carefully educating patients about the possible consequences and effectiveness of treatments may help limit the feeling of treatment regret. PATIENT SUMMARY: In men with localised prostate cancer, regret about the treatment choice was more common among those who experienced more treatment-related symptoms during the year after treatment.
Authors: Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey Journal: Signal Transduct Target Ther Date: 2020-01-31
Authors: Udit Singhal; Ted A Skolarus; John L Gore; Matthew G Parry; Ronald C Chen; Julie Nossiter; Alan Paniagua-Cruz; Arvin K George; Paul Cathcart; Jan van der Meulen; Daniela A Wittmann Journal: Nat Rev Urol Date: 2022-03-08 Impact factor: 16.430
Authors: Spyridon P Basourakos; Keith Kowalczyk; Marcio Covas Moschovas; Vanessa Dudley; Andrew J Hung; Jonathan E Shoag; Vipul Patel; Jim C Hu Journal: J Endourol Date: 2021-11 Impact factor: 2.942
Authors: Donna L Berry; Fangxin Hong; Traci M Blonquist; Barbara Halpenny; Niya Xiong; Christopher P Filson; Viraj A Master; Martin G Sanda; Peter Chang; Gary W Chien; Randy A Jones; Tracey L Krupski; Seth Wolpin; Leslie Wilson; Julia H Hayes; Quoc-Dien Trinh; Mitchell Sokoloff Journal: Urol Oncol Date: 2021-01-19 Impact factor: 2.954
Authors: Barbara M Wollersheim; Kristel M van Asselt; Henk G van der Poel; Henk C P M van Weert; Michael Hauptmann; Valesca P Retèl; Neil K Aaronson; Lonneke V van de Poll-Franse; Annelies H Boekhout Journal: BMC Cancer Date: 2020-07-08 Impact factor: 4.430
Authors: Roman O Kowalchuk; David Hillman; Thomas B Daniels; Carlos E Vargas; Jean-Claude M Rwigema; William W Wong; Bradley J Stish; Amylou C Dueck; Richard Choo Journal: Clin Transl Radiat Oncol Date: 2021-09-15
Authors: Niklas Westhoff; Ramona Ernst; Karl Friedrich Kowalewski; Laura Schmidt; Thomas Stefan Worst; Maurice Stephan Michel; Jost von Hardenberg Journal: World J Urol Date: 2020-06-12 Impact factor: 4.226
Authors: Graham R Hale; Mohammed Shahait; David I Lee; Daniel J Lee; Ryan W Dobbs Journal: Patient Prefer Adherence Date: 2021-06-23 Impact factor: 2.711